SEC Filings
BlackRock Now Holds 7.8% Of Editas Medicine, A Stake Of 11.9 Million Shares
The asset manager's passive filing lists 11,937,882 Editas shares and says none were bought to influence control of the gene-editing company.
SEC Filings
The asset manager's passive filing lists 11,937,882 Editas shares and says none were bought to influence control of the gene-editing company.
SEC Filings
The asset manager's passive ownership filing puts its stake at 527,115 Class A shares as of September 30, 2026.
SEC Filings
The asset manager's passive filing shows sole voting power over 330,149 shares of the cancer and Wilson disease drug developer.
SEC Filings
The asset manager reports 5.01% of the gene-editing company's common stock in a passive ownership filing.
SEC Filings
BlackRock reported 5,339,458 shares of the Crohn's-focused biotech, with sole voting power over 5,221,737 of them.
SEC Filings
The asset manager's passive ownership filing counts the shares as of September 30, with sole voting power over 3,226,537 of them.
SEC Filings
The asset manager certified the holding is for ordinary business, not to influence control of the truck-dealership operator.
SEC Filings
The cruise operator's 10-Q shows a one-year Morgan Stanley bridge behind the deal, with $2.2 billion of debt due within a year.
SEC Filings
The water-equipment maker's quarterly report shows a fully drawn term loan, unfinished deal accounting and a securities class action.
SEC Filings
Total ARCALYST inventory reached $112.7 million at September 30, up from $59.9 million at year-end, as sales climbed.
SEC Filings
The clinical research firm's backlog fell to $32.6 billion after it dropped inactive trials, while new 2034 notes carry a higher coupon.
SEC Filings
Operating cash flow hit $28.4 million as receivables unwound, while employee tax bills took $16.8 million and buybacks halved.